Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis

American Journal of Neuroradiology

Volumn 24, Issue 4, 2003, Pages 658-662

  Sardanelli, Francesco ^a   Iozzelli, Andrea ^b   Losacco, Caterina ^b   Murialdo, Alessandra ^b   Filippi, Massimo ^c  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM CHELATE;

ADULT; ARTICLE; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ENHANCEMENT; INJECTION; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE DRUG DOSE;

ADULT; BRAIN; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVER VARIATION; SENSITIVITY AND SPECIFICITY;

EID: 0037392094     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Miller DH, Barkhof F, Albert PS, et al. Guidelines for the use of magnetic resonance techniques to monitor the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16
2. Molyneux PD, Miller DH. Magnetic resonance imaging techniques to monitor phase III treatment trials. In: Filippi M, Grossman RI, Comi G, eds. Magnetic Resonance Techniques in Clinical Trials in Multiple Sclerosis. Milan: Springer-Verlag; 1999:49-73
3. McFarland HF, Frank JA. The application of magnetic resonance imaging to phase II trials in multiple sclerosis. In: Filippi M, Grossman RI, Comi G, eds. Magnetic Resonance Techniques in Clinical Trials in Multiple Sclerosis. Milan: Springer-Verlag; 1999:37-48
4. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127
5. Tas MW, Barhof F, van Walderveen MAA, Polman CH, Hommes OR, Valk J. The effect of gadolinium on the sensitivity and specificity of MR imaging in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol 1995;16:259-264
6. Tintore M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 2001;7:359-363
7. Losseff N, Kingsley DPE, McDonald WI, et al. Clinical and magnetic resonance predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler 1996;1:218-222
8. Koudriavtseva T, Thompson AJ, Fiorelli M, et al. Gadolinium enhanced MRI disease activity in relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287
9. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis: Gadolinium MRI Meta-analysis Group. Lancet 1999;353:964-969
10. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994;4:141-145
11. Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:540-544
12. Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed MRI in patients with benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526-530
13. Filippi M, Yousry T, Campi, A, et al. Comparison of triple dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379-384
14. Wolansky LJ, Finden SG, Chang R, et al. Gadoteridol in multiple sclerosis patients: a comparison of single and triple dose with immediate vs. delayed imaging. Clin Imaging 1998;22:385-392
15. Rovaris M, Rodegher M, Comi G, Filippi M. Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard- and triple-dose Gd-enhanced MRI. Eur Neurol 1999;41:123-127
16. Rovaris M, Bastianello S, Capra R, Comi G, Yousry TA, Filippi M. Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis. Magn Reson Imaging 1999;17:985-988
17. Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998;121:2011-2020
18. Bastianello S, Gasperini C, Paolillo A, et al. Sensitivity of enhanced MR in multiple sclerosis: effects of contrast dose and magnetization transfer contrast. AJNR Am J Neuroradiol 1998;19:1863-1867
19. Silver NC, Good CD, Sormani MP, et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in multiple sclerosis. J Neurol 2001;248:215-224
20. Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology 1998;50:1289-1293
21. Rovaris M, Mastronardo G, Prandini F, Bastianello S, Comi G, Filippi M. Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans. J Neurol Sci 1999;164:148-152
22. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988;15:266-272
23. Barkhof F, Filippi M, Miller D, et al. Strategies for optimising MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244:76-84
24. Molyneux PD, Filippi M, Barkhof F, et al. Correlation between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339
25. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant humaninterferon-B-1a: Ashort term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258
26. Frank JA, Stone LA, Smith ME, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implication for treatment trials. Ann Neurol 1994;36(Suppl):S86-S90
27. Gasperini C, Paolillo A, Rovaris M, Yousry TA, Capra R, Bastianello S, Filippi M. A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging 2000;18:761-763
28. Sardanelli F, Losacco C, Iozzelli A, et al. Evaluation of Gd-enhancement in brain MR of multiple sclerosis: image subtraction with and without magnetization transfer. Eur Radiol 2002;12:2077-2082